PHVS
Pharvaris N.V. (NASDAQ)
Healthcare — Biotechnology
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Price History
Fundamentals
| Market Cap | $2.37B |
| P/E Ratio (TTM) | - |
| Forward P/E | -12.83 |
| EPS (TTM) | $-3.10 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -73.02% |
| Debt/Equity | 0.31 |
| Recommendation | Strong Buy 1.4 |
| Analyst Target | $46.43 |
| Analysts | 13 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 64.7 |
| Beta | -2.33 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $35.91 |
| 52-Week Low | $17.05 |
| 50-Day Avg | $30.84 |
| 200-Day Avg | $26.87 |
| Avg Volume | 354.2K |
| Volume | 374.4K |
Performance Analysis
BULLISHPHVS shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:26 UTC
Back to Screener Export Report